Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy

This study aims to compare the efficacy and safety of Sacubitril/Valsartan versus Valsartan in patients with essential hypertension and type 2 diabetic nephropathy over a 12-week treatment period, including two treatment groups, with a total of 297 eligible subjects randomly assigned in a 2:1 ratio to either the experimental group or the control group.Subjects will participate in the study through two phases: the screening period and the follow-up period.The primary outcome measure is the change in systolic blood pressure from baseline after 12 weeks of treatment.

NCT Number	NCT06501651
Lead Sponsor	Sichuan Academy of Medical Sciences Collaborators: The Second Affiliated Hospital of Chongqing Medical University, Nanchong Central Hospital, The People's Hospital of Leshan, The Affiliated Traditional Chinese Medicine Hospital Of Southwest Medical University, Chengdu First People's Hospital, Mianyang People's Hospital, Guang'an people's hospital of Sichuan province, Meishan Traditional Chinese Medicine Hospital, Qijiang District People's Hospital, Meishan People's Hospital, The First People's Hospital of Guangyuan, Dazhou Central Hospital
Conditions	Essential Hypertension, Type 2 Diabetes, Nephropathy
Enrollment	297 participants
Start Date	2024-08-01
Primary Completion	2025-04-10 (estimated)
Study Completion	2025-04-10 (estimated)
Updated on ClinicalTrials.gov	2024-07-15